TX Houston의 비호지킨 림프종 임상 시험
비호지킨 림프종 관련 연구 31개가 Houston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
피험자 모집 중1/2상
- Md Anderson Cancer Center, Houston
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
피험자 모집 중1상
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
피험자 모집 중1상
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
피험자 모집 중1상
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
피험자 모집 중관찰 연구
- Texas Children's Hospital, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
피험자 모집 중2상
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
피험자 모집 중1상
- Baylor College of Medicine, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
피험자 모집 중1상
- Md Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
피험자 모집 중1/2상
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
피험자 모집 중2상
- Research Site, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
피험자 모집 중1상
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
피험자 모집 중1상
- Clinical Trial Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
피험자 모집 중1/2상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
피험자 모집 중1/2상
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
피험자 모집 중3상
- MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
피험자 모집 중2상
- The University of Texas MD Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
피험자 모집 중관찰 연구
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
피험자 모집 중1상
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- 외 1개
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
피험자 모집 중1/2상
- The University of Texas MD Anderson Cancer Center, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
피험자 모집 중1상
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
피험자 모집 중4상
- University of Texas MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
피험자 모집 중4상
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
피험자 모집 중1상
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
피험자 모집 중2상
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
피험자 모집 중1/2상
- University of Texas MD Anderson Cancer Center, Houston
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
다른 도시의 비호지킨 림프종 시험
- New York City, NY연구 31개
- Boston, MA연구 26개
- Nashville, TN연구 21개
- Philadelphia, PA연구 20개
- Baldwin Park, CA연구 19개
- Washington, DC연구 18개
- Milwaukee, WI연구 18개
- Atlanta, GA연구 18개
- Chicago, IL연구 18개
- Columbus, OH연구 18개
- Dallas, TX연구 17개
- Seattle, WA연구 16개
Houston의 다른 연구
- 비소세포폐암연구 145개
- 유방암연구 126개
- 암 (전체)연구 121개
- 전이성 암연구 104개
- 대장직장암연구 102개
- 난소암연구 89개
- 급성 골수성 백혈병연구 85개
- 폐암연구 78개
- 전립선암연구 76개
- 자궁내막암연구 68개
- 췌장암연구 61개
- 흑색종연구 59개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.